Global Alpha Emitters Strategic Business Report 2022: Featuring Actinium Pharmaceuticals, Alpha Tau Medical, Bayer and Fusion Pharma Among Others – ResearchAndMarkets.com

Global Alpha Emitters Strategic Business Report 2022: Featuring Actinium Pharmaceuticals, Alpha Tau Medical, Bayer and Fusion Pharma Among Others – ResearchAndMarkets.com




Global Alpha Emitters Strategic Business Report 2022: Featuring Actinium Pharmaceuticals, Alpha Tau Medical, Bayer and Fusion Pharma Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alpha Emitters: Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for Alpha Emitters estimated at US$684.5 Million in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 20.6% over the analysis period 2020-2027.

Bone Metastasis, one of the segments analyzed in the report, is projected to record a 20.1% CAGR and reach US$888.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ovarian Cancer segment is readjusted to a revised 21.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $203.1 Million, While China is Forecast to Grow at 19.9% CAGR

The Alpha Emitters market in the U.S. is estimated at US$203.1 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$437.5 Million by the year 2027 trailing a CAGR of 19.9% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.4% and 17.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR.

Pancreatic Cancer Segment to Record 21.2% CAGR

In the global Pancreatic Cancer segment, USA, Canada, Japan, China and Europe will drive the 21.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$94.5 Million in the year 2020 will reach a projected size of US$357.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 12 Featured) –

  • Actinium Pharmaceuticals, Inc.
  • Alpha Tau Medical
  • Bayer AG
  • Fusion Pharma
  • IBA Group
  • IBA Radiopharma Solutions
  • Lantheus Medical Imaging, Inc.
  • NTP Radiosotopes SOC Ltd.
  • RadioMedix, Inc.
  • Siemens Healthineers
  • Telix Pharmaceuticals Ltd.
  • Triad Isotopes, Inc.

What’s New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies – Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and a Research Platform
  • Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Alpha Emitters – Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/sjgsx1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900